Open AccessHumoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
Author(s) -
Ayelet Grupper,
Nehama Sharon,
Talya Finn,
Regev Cohen,
Meital Israel,
Amir Agbaria,
Yoav Rechavi,
Idit F. Schwartz,
Doron Schwartz,
Yonatan Lellouch,
Moshe Shashar
Publication year - 2021
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.03500321
Subject(s) - medicine , interquartile range , dialysis , hemodialysis , odds ratio , quartile , confidence interval , vaccination , immunology
Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it.